The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy

Radiation Oncology

Table 4 Univariate analysis between clinicopathological parameters and survival

Parameters	Cases	5-year DFS (%)	P value	5-year OS(%)	P value
Gender
Male	71	62.8	0.631	76.7	0.354
Female	41	64.4		67.4
Age
<62	49	64.2	0.615	69.9	0.476
≥62	63	62.7		76.4
Distance from anal verge (cm)
<6	39	59.9	0.375	68.4	0.286
≥6	73	66.1		76.7
Histology
Differentiated	64	68.0	0.267	78.2	0.139
Undifferentiated	48	56.3		66.5
CEA (ng/ml)
<3.4	52	68.2	0.320	77.0	0.380
≥3.4	60	58.9		66.7
Clinical Tumor status
cT3	62	70.0	0.046	81.4	0.021
cT4	50	54.2		59.4
Pathological Tumor status
pT0-2	44	73.3	0.034	83.4	0.019
pT3-4	68	56.8		65.3
Clinical Node status
cN0	38	78.6	0.011	84.0	0.008
cN+	74	51.9		59.5
Pathological Node status
pN0	67	69.4	0.016	79.9	0.024
pN+	45	54.5		61.7
EZH 2
High	53	74.0	0.025	82.8	0.032
Low	59	53.8		64.1

ISSN: 1748-717X